Another lawsuit has been filed against the makers of the well-known heartburn medication Zantac, after a Virginia woman is claiming the drug caused her esophageal cancer.
The woman, Deborah Haskins, has alleged that the medication’s active ingredient, ranitidine, formed dangerous levels of a known carcinogen in her body, leading to the cancer.
Haskins began using Zantac back in 2005, taking it daily. She was later diagnosed with esophageal cancer, allegedly caused by the drug.
Now, she has decided to file a lawsuit against the drug maker for not warning consumers of the potential risks of taking the medication.
Haskin’s also hopes to be compensated for lost wages, piling medical expenses, as well as “loss of enjoyment of life” due to her cancer diagnosis.
Apparently ranitidine can break down during digestion and produce NDMA, which has been linked to several cancers in previous studies.
Zantac’s current and past manufacturers are named in the lawsuit.
AWM reported more on this medication:
Zantac and all ranitidine generic drugs were removed from the market in October 2019 due to the potentially harmful effects of the medication. The FDA claimed that people could take 96 nanograms of NDMA without consequences. An independent test of Zantac found it contained NDMA “in excess of 3,000,000 nanograms per tablet.”
Following the FDA disclosure, pharmacy chains like CVS Health, the Kroger Company, Rite Aid, and Walgreens announced that they would be suspending the sale of Zantac and their genetic versions.
Before the FDA announcement, Zantac was a best-selling drug. It was worth about $128.9 million in 2018. Haskins’s lawsuit joins about a dozen others against the Paris-based manufacturer.
Watch the video report here: CBS Newyork/Youtube